Karen Knudsen: New U.S. Investments in Virginia Site will Expand Capacity and Save More Lives
Karen Knudsen, Chief Executive Officer at Parker Institute for Cancer Immunotherapy, shared a post on LinkedIn:
“What a week!
There’s nothing more inspiring than seeing the journey from scientific discovery to patient impact, live and in person. Just returned from time with exceptional CEO Pascal Soriot and my fellow AstraZeneca Board members at our Maryland sites – complete with AZ scientific and business leaders, a town hall with the Maryland team, and a tour of the Frederick Manufacturing Center. We kicked it all off with our announcement re: a new U.S. investments, including a Virginia site made that will expand capacity and save more lives.
Kudos to the global AZ team, who are science-led, patient-focused, and dedicated to improving lives.”
More posts featuring Karen Knudsen.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023